CorrespondenceAnti-CD20 (rituximab) treatment for atopic eczema
References (7)
- et al.
Anti-CD20 (rituximab) treatment improves atopic eczema
J Allergy Clin Immunol
(2008) - et al.
Treatment of rheumatoid arthritis with rituximab: an update and possible indications
Autoimmun Rev
(2006) Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)
J Am Acad Dermatol
(2004)
Cited by (82)
Biologics for Atopic Dermatitis
2020, Immunology and Allergy Clinics of North AmericaRole of B cells in immune-mediated dermatoses
2020, Molecular ImmunologyCitation Excerpt :There are also disappointing results. The study include 2 AD patients discovered that there was no significant improvement at the dose of twice of 0.5 g in a 2 weeks apart (Sediva et al., 2008). Further double-blind placebo-controlled research is essential to state whether rituximab can be an option for the therapy of AD.
Clinical approach to the patient with refractory atopic dermatitis
2018, Annals of Allergy, Asthma and ImmunologyCitation Excerpt :Similarly, there have been mixed results found for ustekinumab.64 a monoclonal antibody that blocks IL-12 and IL-23, and rituximab, a monoclonal antibody to CD20.65 Dupilumab is a monoclonal antibody that blocks the α-subunit of IL-4 receptor α, thus effectively blocking the actions of IL-4 and IL-13, which are key cytokines involved in the development of AD.
Biologic Therapy for Atopic Dermatitis: Moving Beyond the Practice Parameter and Guidelines
2017, Journal of Allergy and Clinical Immunology: In PracticeCitation Excerpt :Although total serum IgE levels were reduced, allergen-specific IgE levels were not affected. In contrast, treatment with rituximab 500 mg intravenously given twice over a 2-week interval to 2 patients with severe AD resulted in only a transient improvement in clinical scores followed by deterioration.68 A treatment protocol combining omalizumab and rituximab in patients with severe refractory AD was found to be effective, suggesting that optimal therapy may require the use of several biologics in certain patients.66
Biologics in patients with skin diseases
2017, Journal of Allergy and Clinical ImmunologyCellular and molecular immunologic mechanisms in patients with atopic dermatitis
2016, Journal of Allergy and Clinical ImmunologyCitation Excerpt :Allergen immunotherapy has only a modest efficacy on AD.83,171 Nevertheless, in recent years, the main therapeutic concepts, besides repairing the epidermal barrier or influencing the microbiome, target acute-phase inflammation or TH2 immunity (Table II).24,27,47,70,172-183 A breakthrough came with dupilumab, an antibody targeting the IL-4 receptor α chain, which is the overall most efficient therapy on the basis of available data from clinical studies.27,174
Supported by Research Project VZ 00064203, Ministry of Health, Czech Republic.
Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.